Brain/Neuro Cancer: Recurrent Glioblastoma Clinical Trials

Showing 1-12 of 12 items
1.
2.
3.
4.
  • Pembrolizumab +/- Bevacizumab for Recurrent GBM
  • In this research study, the investigators are looking to determine the effectiveness of Pembrolizumab (MK-3475) when given with bevacizumab or when given alone for the treatment of recurrent glioblastoma multiforme (GBM). This study will also test the safety and tolerability of Pembrolizumab (MK-3475) when given alone or with bevacizumab.
  • Diagnoses: Brain/Neuro Cancer: Recurrent Glioblastoma
  • Status: Recruiting
5.
  • PF-00299804 in Adult Patients With Relapsed/Recurrent Glioblastoma
  • There are three arms to this study (A, B and C) The purpose of this research study during Arm A is to see how much of PF-00299804 gets into the brain tumor. For many brain tumors, one reason that chemotherapy drugs might not be effective is that the drug may not be able to get into the brain tumor and kill the cancer cells. We will determine how much PF-00299804 gets into the brain tumor by obtaining a sample of the tumor from the surgery that the participant already has scheduled. The purpose of this research study during Arm B and C, is to determine how well PF-00299804 works in killing cancer cells. PF-00299804 works by binding to specific proteins found on the surface of some cancer cells that promote a growth signal. Blocking this signal from reaching its target on the cancer cells may slow or stop the cancer from growing.
  • Diagnoses: Brain/Neuro Cancer: Recurrent Glioblastoma
  • Status: Recruiting
6.
  • Phase Ib/II Study of Buparlisib Plus Carboplatin or Lomustine in Patients With Recurrent Glioblastoma Multiforme
  • This is a multi-center, phase Ib/ II study (two parts) with patients that have recurrent glioblastoma multiforme. The first part (phase Ib) will investigate the maximum tolerated dose/Recommended phase ll dose (MTD/RP2D) of once daily buparlisib in combination with every-three-week carboplatin or buparlisib once daily in combination with every-six-week lomustine (CCNU) using a Bayesian model. Once MTD/ RP2D is established in either of the 2 arms, the corresponding phase II portion of the study will start. Phase II will assess the treatment effect of buparlisib in combination with carboplatin in terms of Progression Free Survival (PFS) and will compare the treatment effect of buparlisib with lomustine versus lomustine plus placebo in terms of PFS.
  • Diagnoses: Brain/Neuro Cancer: Recurrent Glioblastoma
  • Status: Recruiting
7.
8.
9.
  • Plerixafor (AMD3100) and Bevacizumab for Recurrent High-Grade Glioma
  • Plerixafor in combination with bevacizumab is a drug combination that may stop cancer cells from growing abnormally. Bevacizumab, also known as Avastin, is FDA approved for use in patients with recurrent glioblastoma and has been studied extensively in other types of solid tumors. Plerixafor, also known as Mozobil, is FDA approved for use in patients with non-Hodgkin's lymphoma and multiple myeloma and has been used in treatment for other cancers. Information from experiments in laboratories suggests that the combination of plerixafor and bevacizumab may help prevent the growth of gliomas. Part 1: The investigators are looking for the highest dose of plerixafor that can be given safely with bevacizumab (with a 21 days on/7 days off regimen of plerixafor). The investigators will also do blood tests to find out how the body uses and breaks down the drug combination. Part 2: The investigators are looking to see if plerixafor can get past the blood-brain barrier and into brain tumors. The investigators will also do blood tests to find out how the body uses and breaks down the drug combination. Part 3: The investigators are looking for for more information re: safety and tolerability of plerixafor in combination with bevacizumab (with a 28 days on/0 days off regimen of plerixafor). The investigators will also do blood tests to find out how the body uses and breaks down the drug combination.
  • Diagnoses: Brain/Neuro Cancer: Recurrent Glioblastoma
  • Status: Recruiting
10.
11.
  • Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma
  • This randomized phase II trial studies how well bevacizumab with or without radiation therapy works in treating patients with recurrent glioblastoma. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry cancer-killing substances to them. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. It is not yet know whether bevacizumab is more effective with or without radiation therapy in treating patients with recurrent glioblastoma
  • Diagnoses: Brain/Neuro Cancer: Recurrent Glioblastoma
  • Status: Recruiting
Showing 1-12 of 12 items
  • Email
  • Print
  • Share
  • Text
Highlight Glossary Terms